Introduction {#sec1-1}
============

Obesity represents one of the major Public Health problems. Obese children had a shorter life expectancy by 20 years if they remain obese till young adulthood \[[@ref1]\]. North African Countries and the region of Middle East just like the other developing countries are not spared from the issue of the world \[[@ref2], [@ref3]\]. Genetics, metabolic, social, cultural and environmental factors interact as different cofactors for the development of obesity. The prevalence of obesity in Egyptian children ranged from 13.5 % up to 23.7% \[[@ref4]-[@ref5]\].

Advanced knowledge of human genome variations led to identification of genes susceptible to contribute in obesity and other related diseases; meanwhile few studies focused specifically on the interactions between obesity and genetic polymorphism \[[@ref6]\]. Interleukin-6 (IL-6) is an immune-modulator pro-inflammatory cytokine involved in the regulation of the acute phase response \[[@ref7]\]. High IL-6 serum level was found in obese patients as well as patients suffering chronic inflammatory conditions and serum lipid concentrations abnormalities \[[@ref8]\]. Interleukin-6 production has been shown to be significantly increased by adipose tissue in a state of obesity. The increased IL-6 levels in obese individuals may result in a state of insulin resistance and increased risk of cardiovascular complication \[[@ref9]\].

Plasmatic levels of cytokines and its transcriptional regulation is influenced by the polymorphisms of IL-6 (especially174G/C) as proved in many population groups based genetic studies, that have been performed to figure out whether there is an association between obesity and *IL-6* (*174G/C*) polymorphisms, but results were not conclusive with a lot of controversies \[[@ref10]-[@ref11]\].

Based on this; this study aimed to find out whether *IL6 (174G/C)* polymorphisms designated as rs1800795 as well, is associated with the risk of developing obesity in Egyptian children.

Subjects and Methods {#sec1-2}
====================

This is a cross-sectional study that included one hundred and forty-nine children and adolescents, 71 males and 78 females. Their age ranged between 9.5 to 18 years (mean 11.72 ± 2.52 yrs). This study started by one thousand children and adolescents chosen randomly from three governmental schools at Giza. According to their anthropometric measures, it was found that one hundred and thirty were obese (BMI-Z score \>2). Eighty-five of them (41 males and 44 females) were fulfilling the criteria and gave the consent to share in the study.

*Exclusion criteria:* were factors that might lead to the misclassification of a child's weight status, that are: (1) an acute or chronic illness affecting weight; (2) genetic conditions associated with obesity or failure to thrive; and/or (3) use of medications associated with weight gain or loss.

*Inclusion criteria:* apart from obesity; all obese subjects and non-obese controls were in good health. This study was a part of project that approved by the Medical Ethical Committee of the National Research Center with registration number 14046. All participants were informed about the objectives of the study and volunteered to participate and the parents of all subjects provided a written informed consent.

Anthropometric assessments {#sec2-1}
--------------------------

Anthropometric assessments were performed according to techniques described in the Anthropometric Standardization Reference Manual \[[@ref12]\]. Weight was measured using a calibrated Seca scale to the nearest 0.1 kg (Seca, Hamburg, Germany), whereas height (in cm) was measured using a Seca 225 stadiometer to the nearest 0.1 cm, with the children dressed in minimal clothes and without shoes. Each measurement was taken as the mean of three consecutive readings following the recommendations of the International Biological Program \[[@ref13]\]. Weight for height, weight for age, height for age, and BMI for age was recorded according to WHO standards using Anthro Plus software for personal computers \[[@ref3]\]. Measurements were expressed as weight-for-age Z-score (WAZ), height for age Z-score (HAZ), and BMI Z-score (BAZ). The participants were then grouped according to the WHO Global Database on Child Growth and Malnutrition using a Z-score cut-off point \[[@ref14]\]: Overweight and obese children with BAZ \>2 and control children with BAZ ≤ 2.

Laboratory Investigations {#sec2-2}
-------------------------

Fasting blood sample was drawn from each participant into vacutainer tube containing EDTA as an anticoagulant. The samples were immediately transferred to the laboratory, centrifuged immediately for 10 min at 4000 and stored at −80°C.

\- Serum interleukin-6 level measuring using the quantitative Enzyme-Linked Immune-Sorbent Assay (ELISA) with a commercial kit provided by DIA source, Belgium \[[@ref15]\].

\- DNA extraction: Blood samples were collected on Na~2~EDTA as an anticoagulant. Genomic DNA was purified from 200 μl whole blood with the QIAamp® DNA Blood Mini Kit (Qiagen) according to the Blood and Body Fluid Spin Protocol in the accompanying handbook. DNA was eluted in 200 μl elution buffer and stored at --20°C.

\- Detection of *IL6 (-174G/C)* polymorphism: DNA was amplified with primers specific for *-174G/C* (rs1800795) in a 25 μl reaction mixture containing ; 50 ng μL genomic DNA, ddH~2~O 15.7 μL, 10 x buffer 2.5 μL, dNTP (10 mmol) 0.5 μL, each of primer sequences (10 μmol) 0.5 μL, MgCL~2~ (25 mmol) 2 μL and 1U Taq enzyme. The PCR was performed in 30 cycles; (95°C for 30 sec, annealing at 55°C for 30 s, and extension at 72°C for 1 min), with an initial denaturation at 95°C for 5 min and a final extension at 72°C for 10 min. Followed by final extension 72°C for 5 min. All PCR products were analyzed by 2% agarose gel electrophoresis.

\- Enzyme digestion: Post PCR--RFLP was done by incubating five μl of SNP-PCR product with the restriction enzyme *NIa III* at 37 °C for 30 min. The digested SNP-PCR product was electrophoresed on 3% agarose gel \[[@ref16]\].

Statistical analysis {#sec2-3}
--------------------

The data were analyzed using statistical package for social sciences (SPSS) version 16. Results were presented as mean ± SD, except where otherwise indicated. Comparisons between groups were done by independent samples t-test. Chi-square test was used to estimate differences in qualitative variables. Pearson correlation test was used to determine the relationship between some numerical variables. For all tests, probability values (P) of less than 0.05 were regarded as statistically significant.

Results {#sec1-3}
=======

The characteristics of the studied groups are shown in [Table 1](#T1){ref-type="table"}. The mean serum level of IL-6 in obese children was significantly higher as compared to those of control children (7.7 ± 0.46 pg/mL and 5.46 ± 0.40 pg/mL respectively (P = 0.003). Serum IL-6 level had a positive correlation with age (r = 0.28 and p = 0.001) and with BAZ (r = 0.188 and p = 0.03).

###### 

Characteristics of the studied groups

  Parameter               Controls      Obese        P
  ----------------------- ------------- ------------ ------
  Number                  64            85           
  Males: females          30:34         41:44        ns
  Mean age (years)        10.9 ± 2.3    12.3 ± 2.4   ns
  Z-score BMI (kg/m^2^)   o.13 ± 0.16   2.8 ± 0.62   0.00
  IL-6 (pg/ml)            5.46 ± 0.40   7.7 ± 0.46   

P value ≤ 0.05 is significant.

Result of genotyping analysis of IL6-174G/C polymorphism {#sec2-4}
--------------------------------------------------------

The Nla III restriction enzyme digest the 500 bp applicant of the IL6-174; where *G* allele yielded three bands (of 264, 207 and 29bp); the -174 *C* allele yielded four bands (of 264, 122, 85 and 29 bp) ([Figure 1A](#F1){ref-type="fig"} & [1B](#F1){ref-type="fig"}).

![A) Agarose gel (3%) photographs of PCR-RFLP products (amplicons digested with restriction enzymes) depicting the genotypes of IL-6 polymorphisms PCR and digestion products run on 3% agarose gel electrophoresis. Lane 1: ΦX 174 marker/Hae III digest. Lane 2: The PCR amplified product (500 bp). Lanes 3, 4, 6 and 8: G/G genotype (264, 207 and 29 bp). Lanes 5, 7, and 9: G/C genotype (264, 207 and 122 bp); B) Fig (2): PCR and digestion products run on 3% agarose gel electrophoresis. Lane 1: ΦX 174 marker / Hae III digest. Lane 2: The PCR amplified product (500 bp). Lanes 3, 4, 6, 7, 8, 9, 10, 12: G/C genotype (500, 264, 122 and 85 bp)](OAMJMS-5-831-g001){#F1}

[Table 2](#T2){ref-type="table"} shows the distribution of genotype for *IL6 (-174G/C)* polymorphism: The homozygote genotype *(G/G)* was 57.05 %, the heterozygote *(G/C)* 42.95 % and none of our patients was carrying the homozygote genotype *(C/C)*.

###### 

The frequency of genotype of *IL-6* polymorphism

                      Frequency   Percent
  ------------------- ----------- ---------
  Heterozygous *GC*   64          42.95
  Homozygous *GG*     85          57.05
  Total               149         100

No significant difference in the serum level of *IL-6* between subjects with IL-6 (174G/C) polymorphism and those with IL6 (174G/G) polymorphism ([Table 3](#T3){ref-type="table"}).

###### 

The mean serum level of *IL-6* in both groups of polymorphism

  Parameter                GC            GG            P
  ------------------------ ------------- ------------- ----
  IL-6 (pg/ml) Mean ± SD   6.53 ± 4.97   6.99 ± 4.52   ns

[Table 4](#T4){ref-type="table"} shows that the mean of BMI Z score was significantly higher in *IL-6* polymorphism *GC* as compared to that of polymorphism *GG*. Our results showed that 95.3 % of *IL-6* polymorphism *GC* was found in obese subjects as compared to 4.7 % in normal weight children.

###### 

The mean ±SD of BMIZ-score (BAZ) in both types of *IL-6* polymorphism

  Parameter               GC            GG           P
  ----------------------- ------------- ------------ ------
  BMIZ-score, Mean ± SD   2.76 ± 0.68   0.86 ± 1.6   0.00

P value ≤ 0.05 is significant.

On the other hand, 71.8 of *IL-6 (174G/G)* polymorphism were found in controls as compared to 28.2% in obese children ([Table 5](#T5){ref-type="table"}). It was noted in the results that, none of our children were carrying *C/C* genotyping.

###### 

The percentage of *IL-6* polymorphism in obese and control groups

  *IL-6* polymorphism   Controls   Obese   P           
  --------------------- ---------- ------- ---- ------ ------
  *GG* (n=85)           61         71.8    24   28.2   0.00
  *GC* (n=64)           3          4.7     61   95.3   0.00

Discussion {#sec1-4}
==========

This study revealed a significantly higher serum level of IL-6 in obese children as compared to those of controls. The Same finding was previously reported in a study of Filippo et al. \[[@ref11]\]. Our data showed a positive correlation of IL-6 with both age and BAZ.

These results are by the results of Diego et al. \[[@ref17]\] and Paltoglou et al. \[[@ref18]\]. In this work, we studied whether the *IL6(174G/C)* gene is associated with the risk of developing obesity in obese Egyptian children. The analysed polymorphism *(174G/C)* is localised in the promoter region of the *IL-6* gene, where transcription factors frequently exert their functions through its influence on the energy expenditure processes by different ways. The results revealed that the *GG* homozygote genotype is predominated in the control group (95.3 %) with a statistically significant difference compared to that of obese children (28.2 %). If we considered the *GC* genotypes as *C* carrier; so, the study showed a prevalence 71.8 % (61 of 85), of this C allele among the obese children as compared with 4.7% (3 of 64) in the normal weight children. So, the examined polymorphisms of the pro-inflammatory cytokine *IL-6 (174G/C)* could play a role in the regulation of body mass. According to these aspects, the results of this study seem to confirm the hypothetical relation between the *IL6 (174G/C)* genotype and the risk of developing obesity among Egyptian children.

Our data match and is replicated with previously published data; as some authors have investigated the relation between polymorphisms in *IL-6* gene and obesity based on experimental evidence on mice suggested an influence on fat mass, fat metabolism, and body mass and on the development of obesity \[[@ref19]\]. Zhangbin et al., \[[@ref20]\] realized that *IL-6 (174 G/C)* polymorphism was also associated with obesity by covering 48 studies with outcome similar to the results in our study.

In a study of Popko et al., \[[@ref21]\] the detected *C* allele in both *C/C* homozygotes and G/C heterozygotes of *IL6 (174 G/C)* gene was related to a significant increase in the sum of 10 skinfold thickness measurements in obese girls; which is consistent with the results of our study. A study enrolling Greek school children had shown an association of the IL-6 variant rs1800795 with parameters related to obesity \[[@ref22]\]. Oana et al. \[[@ref23]\] described the *G* allele at *C-174* as being more common in lean subjects and observed the *C* allele to be associated with indices of obesity. These findings are in concordance with the results of our study, in which the *GC* heterozygote genotype predominated in the obese group, and the *GG* genotype was less pronounced in this group than in the normal weight group. In this study, none of our children was carrying *C/C* genotyping. This is because it is a pilot study and our sample size was small. It was previously reported by Saxena et al. \[[@ref24]\] that *CC* genotype was very rare in their study.

Contrary to our findings, data reported in an Iranian study among 242 persons, sustained more frequent *G* alleles in the obese but was statistically insignificant \[[@ref25]\]. Another meta-analysis didn't find significant associations of *IL6 (174G/C)* genotypes with waist-to-hip ratio, waist circumference, or central obesity and did not support a role for this polymorphism in adiposity \[[@ref26]\].

In conclusion, our study showed that carriers of the *C* allele for the *IL-6* polymorphism *G174C* have higher BMI. As the *G174C* gene polymorphism is likely to affect *IL-6* expression and its physiological regulation; consequently this polymorphism may affect adiposity and insulin sensitivity. It is recommended in future studies for the *IL-6* polymorphism *G174C* to be done in a wider scale of children and adolescents and in different demographic areas as our study enrolled relatively small number of obese and normal children which decreased the power of the group in statistic results.
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